DNA testing firm 23andMe files for bankruptcy protection
DNA testing firm 23andMe has filed for bankruptcy protection in the US, marking the collapse of one of the most high-profile names in consumer genetics. Co-founder Anne Wojcicki has stepped down as chief executive with immediate effect, though she will remain on the board.
DNA testing firm 23andMe files for Chapter 11 bankruptcy to sell itself
Genetic testing firm 23andMe filed for Chapter 11 bankruptcy in the U.S. on Sunday and said it was looking to sell itself.
Ginkgo Bioworks Holdings, Inc. (DNA) Surpasses Market Returns: Some Facts Worth Knowing
Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $7.27, moving +1.39% from the previous trading session.
After Plunging -52.33% in 4 Weeks, Here's Why the Trend Might Reverse for Ginkgo Bioworks (DNA)
The heavy selling pressure might have exhausted for Ginkgo Bioworks (DNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
VW's cheapest EV will have Rivian DNA and who is bidding for Canoo's assets
Welcome back to TechCrunch Mobility — your central hub for news and insights on the future of transportation. Sign up here for free — just click TechCrunch Mobility!
Resilience is part of our DNA, says Merck KGaA CEO
Belén Garijo, CEO of Merck KGaA, said the German pharmaceutical company has increased its readiness to deal with the ongoing geopolitical uncertainty, and is confident it will continue delivering profitable growth in 2025.
Ginkgo Bioworks (DNA) Upgraded to Buy: Here's Why
Ginkgo Bioworks (DNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ginkgo Bioworks: Revenue Struggles Continue
Ginkgo Bioworks missed Q4 revenue estimates and issued extremely weak 2025 revenue guidance. Despite improving losses and cash burn, financial flexibility is decreasing, with cash reserves dropping significantly over the past year. The company's valuation is low, but declining revenues and high stock-based compensation pose risks.
2025 Is Make Or Break For Ginkgo Bioworks
Ginkgo Bioworks' restructuring has resulted in a dramatic reduction in cash burn in recent quarters. Ginkgo remains a long way from breakeven though and growth is expected to be poor in 2025. Unless Ginkgo can demonstrate continuous progress in 2025, its stock is likely to remain under pressure due to its shrinking cash runway.
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2024 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q4 2024 Earnings Conference Call February 25, 2025 5:30 PM ET Company Participants Joseph Fridman - Director, Communications and Corporate Affairs Jason Kelly - Founder, CEO & Director Mark Dmytruk - CFO Jason Kelly - Founder, CEO & Director Conference Call Participants Jason Lai - Morgan Stanley Evie Kslosky - Goldman Mark Massaro - BTIG Brendan Smith - TD Cowen Matt Larew - William Blair & Company Joseph Fridman Good evening. I'm Joseph Fridman, Director of Communications and Corporate Affairs here at Ginkgo, where it's my fifth year.
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Misses Revenue Estimates
Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to loss of $3.60 per share a year ago.
Strength Seen in Ginkgo Bioworks (DNA): Can Its 14.5% Jump Turn into More Strength?
Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
